1. Home
  2. ELVN vs NMM Comparison

ELVN vs NMM Comparison

Compare ELVN & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • NMM
  • Stock Information
  • Founded
  • ELVN 2016
  • NMM 2007
  • Country
  • ELVN United States
  • NMM Greece
  • Employees
  • ELVN N/A
  • NMM N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • NMM Marine Transportation
  • Sector
  • ELVN Health Care
  • NMM Consumer Discretionary
  • Exchange
  • ELVN Nasdaq
  • NMM Nasdaq
  • Market Cap
  • ELVN 927.8M
  • NMM 959.8M
  • IPO Year
  • ELVN 2020
  • NMM 2007
  • Fundamental
  • Price
  • ELVN $17.77
  • NMM $39.20
  • Analyst Decision
  • ELVN Strong Buy
  • NMM Strong Buy
  • Analyst Count
  • ELVN 4
  • NMM 1
  • Target Price
  • ELVN $37.25
  • NMM $80.00
  • AVG Volume (30 Days)
  • ELVN 361.5K
  • NMM 83.5K
  • Earning Date
  • ELVN 05-14-2025
  • NMM 05-07-2025
  • Dividend Yield
  • ELVN N/A
  • NMM 0.51%
  • EPS Growth
  • ELVN N/A
  • NMM N/A
  • EPS
  • ELVN N/A
  • NMM 11.23
  • Revenue
  • ELVN N/A
  • NMM $1,319,623,000.00
  • Revenue This Year
  • ELVN N/A
  • NMM N/A
  • Revenue Next Year
  • ELVN N/A
  • NMM $7.93
  • P/E Ratio
  • ELVN N/A
  • NMM $3.49
  • Revenue Growth
  • ELVN N/A
  • NMM 0.28
  • 52 Week Low
  • ELVN $13.30
  • NMM $28.37
  • 52 Week High
  • ELVN $30.03
  • NMM $65.89
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 49.54
  • NMM 58.59
  • Support Level
  • ELVN $15.81
  • NMM $37.81
  • Resistance Level
  • ELVN $17.54
  • NMM $39.90
  • Average True Range (ATR)
  • ELVN 1.30
  • NMM 1.15
  • MACD
  • ELVN -0.04
  • NMM -0.07
  • Stochastic Oscillator
  • ELVN 38.06
  • NMM 37.77

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests

Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.

Share on Social Networks: